Abe T, Tsuda S, Takino T
Gan No Rinsho. 1984 Sep;30(12 Suppl):1543-52.
Recently, there has been much concern that cancer chemotherapy may have undesirable consequences in the form of secondary malignancies. At present, secondary leukemia or therapy-linked leukemia constitutes a well delineated clinical syndrome characterized by several distinct symptoms, that was illustrated by the presentation of cases recently observed. In an attempt to understand the basis for this therapy-linked leukemia, mutagenic activity of various anticancer agents were studied by the induction of sister chromatid exchanges and risk of a certain drug as a possible candidate causing secondary leukemia was discussed from the molecular cytogenetic point of view. From both clinical and cytogenetic aspects it seemed that bifunctional alkylating agents were potentially relevant to the development of secondary leukemia.
最近，人们非常担心癌症化疗可能会以继发性恶性肿瘤的形式产生不良后果。目前，继发性白血病或治疗相关白血病构成了一种明确界定的临床综合征，其特征为几种不同的症状，最近观察到的病例展示说明了这一点。为了理解这种治疗相关白血病的发病基础，通过诱导姐妹染色单体交换研究了各种抗癌药物的诱变活性，并从分子细胞遗传学角度讨论了某种药物作为可能导致继发性白血病的候选药物的风险。从临床和细胞遗传学两方面来看，双功能烷化剂似乎与继发性白血病的发生潜在相关。
